Endostar Combination With Chemotherapy for the Metastatic Nasopharyngeal Carcinoma
Status:
Unknown status
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The investigators designed this study to evaluate the efficiency and the acute toxicities of
recombinant human endostatin (endostar) combined with chemotherapy in the metastatic
nasopharyngeal carcinoma (NPC).